Intestinal transplantation.
In contrast to other solid organ transplantations slow progress has been seen in introducing intestinal transplantation (IT) from an experimental level to clinical practice. In nine years less than 200 transplantations have been performed worldwide with a three-years, survival of approximately 40%. The main problem of IT is immunological. Large amounts of lymphatic tissues transplanted along with the intestinal graft increase the risk of acute rejection and necessitate high doses of immunosuppressive regimens liable of inducing serious side-effects. The immunocompromized recipient is vulnerable to various infections, particularly cytomegalovirus (CMV) enteritis of the graft. However, improved results are expected after introducing modern potent immunosuppressive drugs such as combination of tacrolimus and mycophenolic acid. Emphasized antiviral prophylaxis and treatment, improved preservation and prevention of ischaemia reperfusion injury are other means presently available to obtain better results after intestinal transplantation in the near future. Intestinal transplantation is becoming the treatment of choice in intestinal failure when total parenteral nutrition (TPN) fails for one reason or an other.
Mäkisalo
H
H
Department of Surgery, Helsinki University Central Hospital, Finland.
Ericzon
B G
BG
D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D007421:Intestine, Small / Q000637:transplantation*; D008286:Malabsorption Syndromes / Q000601:surgery*; D010289:Parenteral Nutrition, Total; D011183:Postoperative Complications; D012778:Short Bowel Syndrome / Q000601:surgery*